Literature DB >> 16248836

Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

E Fontana1, P M Dansette, S M Poli.   

Abstract

The inhibition of human cytochrome P450s (CYPs) is one of the most common mechanisms which can lead to drug-drug interactions. The inhibition of CYPs can be reversible (competitive or non-competitive) or irreversible. Irreversible inhibition usually derives from activation of a drug by CYPs into a reactive metabolite, which tightly binds to the enzyme active site, leading to a long lasting inactivation. This process is called "mechanism based inhibition" or "suicide inhibition". The irreversible inactivation usually implies the formation of a covalent bond between the metabolite and the enzyme, which can lead to hapten formation and can in some cases trigger an autoimmune-response. For these reasons it is of utmost importance to study the mechanism of the CYP inhibition of new potential drugs as early as possible during the drug discovery process. The literature on CYPs is vast and covers numerous aspects of their biology and biochemistry, however to our knowledge there is no general and systematic review focusing on mechanism-based inhibitors; we have reviewed the literature and compiled all the available data on chemical entities, which are known to be CYP suicide inhibitors. Each compound is reported together with its chemical structure, the CYP isoform and the parameters describing the inactivation. Literature references are reported together with their PMID (PubMed ID number) to allow a fast retrieval of the papers. This review offers a quick reference to help predict liabilities of new chemical entities without carrying out extensive in vitro work, and will hopefully help in designing safer drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16248836     DOI: 10.2174/138920005774330639

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  25 in total

1.  An in vivo assay for elucidating the importance of cytochromes P450 for the ability of a wild mammalian herbivore (Neotoma lepida) to consume toxic plants.

Authors:  Michele M Skopec; Jael R Malenke; James R Halpert; M Denise Dearing
Journal:  Physiol Biochem Zool       Date:  2013-08-14       Impact factor: 2.247

Review 2.  Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

Authors:  Stig Thunell; Erik Pomp; Atle Brun
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

Review 3.  The conduct of drug metabolism studies considered good practice (II): in vitro experiments.

Authors:  Lee Jia; Xiaodong Liu
Journal:  Curr Drug Metab       Date:  2007-12       Impact factor: 3.731

Review 4.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

Review 5.  Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Authors:  David J Greenblatt; Jerold S Harmatz
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

6.  Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Delta7-24, 25-dihydrolanosterol.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Jialin Liu; Michael R Waterman; W David Nes; Galina I Lepesheva
Journal:  J Lipid Res       Date:  2011-11-30       Impact factor: 5.922

7.  Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.

Authors:  Jelle Reinen; Martijn Smit; Mira Wenker
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

8.  Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.

Authors:  Pierre Lafite; Sylvie Dijols; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Arch Biochem Biophys       Date:  2007-04-10       Impact factor: 4.013

9.  Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Mol Pharm       Date:  2018-04-10       Impact factor: 4.939

Review 10.  The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

Authors:  Brooke M VandenBrink; Nina Isoherranen
Journal:  Curr Opin Drug Discov Devel       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.